

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart



ADVANCED/METASTATIC

■ Open to Accrual

■ Low Accruing

■ Pending Activation

1L

UCI 24-192 (Nuvalent)

NVL-655 vs Alectinib

Mechanism: ALK inhibitor
Coord: Mindy Chen
PI: Dr. Nagasaka
Accrual: 0/5

2L

UCI 21-241 (Nuvalent)

NVL-655 + ALK inhibitor

Mechanism: ALK Inhibitor
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-51 (Nuvalent)

NVL-655 EAP

Mechanism: ALK inhibitor
Coord: To be determined
PI: Dr. Park
Accrual: 0/7



ADVANCED/METASTATIC

Exon 18

Open to Accrual

Low Accruing

Pending Activation

Exon 19 del or L858R

1L

UCI 24-169
(BlossomHill
Therapeutics)
BH-30643 Capsule

Mechanism: EGFR or
HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 8/10

UCI 24-169
(BlossomHill
Therapeutics)
BH-30643
Capsule

Mechanism:
EGFR or
HER2 TKI
Coord: Celest
Ramirez
PI: Dr.
Nagasaka
Accrual: 8/10

UCI 24-181
(Janssen
Research &
Development)
Amivantamab +
Lazertinib
Mechanism:
EGFR TKI
Coord:
Stephanie
Fernandez
PI: Dr. Park
Accrual: 1/6

UCI 22-217
(Janssen)
Amivantamb +
Lazertinib w/
or without Carbo +
Pemetrexed

Mechanism:
Antibody drug w/
TKI and Chemo
Coord: Richard
Chang
PI: Dr. Nagasaka
Accrual: 5/15

2L

UCI 23-178
BL-B01D1 IV
Mechanism:
EGFR and/or
HER3
bispecific
antibody
Coord: Cassie
Smith
PI: Dr. Park
Accrual: 5/10



Exon 20

Exon 21

1L

UCI 22-217(Janssen)Amivantamb + Lazertinib w/ or
without Carbo + PemetrexedMechanism: Antibody drug w/ TKI
and Chemo
Coord: Richard Chang
Dr. Nagasaka
Accrual: 5/15UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism: EGFR
or HER2 TKI
Coord: Celest
Ramirez
Dr. Nagasaka
Accrual: 8/10UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism:
EGFR or HER2 TKI
Coord: Celest
Ramirez
Dr. Nagasaka
Accrual: 8/10UCI 24-181 (Janssen Research
& Development)Amivantamab + Lazertinib
Mechanism: EGFR TKI
Coord: Stephanie Fernandez
Dr. Park
Accrual: 1/6

2L



ADVANCED/METASTATIC

1L

UCI 23-66 (Boehringer
Ingelheim)
BI-1810631
Monotherapy

Mechanism: TKI
Cord: Cassie Smith
Dr. Nagasaka
Accrual: 2/5

2L

Exon 18

Exon 19

Exon 20

Exon 21

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 8/10

UCI 23-178

BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody
Coord: Cassie Smith
PI: Dr. Park
Accrual: 5/10



Early Stage

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-79 (Beamion Lung-3)

Zongertinib vs SOC

Mechanism: TKI

Coord: To be determined

PI: Dr. Arter

Accrual: 0/3

ADVANCED/METASTATIC

 Open to Accrual Low Accruing Pending Activation

KRAS G12C

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
Coord: Cassie Smith
Dr. Nagasaka
Accrual: 3/5

UCI 25-88 (Part A:
Olomorasib w/ Pembro or
Placebo w/ Pembro. Part B:
Durvalumab w/ Pembro or
Placebo w/ Durvalumab)

Mechanism: TKI and Anti-PD-
1 / Anti-PD-L1
Coord: TBD
PI: Dr. Park
Accrual: 0/5

2L

UCI 21-53 (Loxo Oncology,
Inc. LOXO-RAS-20001

Mechanism: TKI
Coord: Mindy Chen
Dr. Nagasaka
Accrual: 9/12

G12A, G12D, G12R, G12S, G12V

UCI 24-157 (RMC-6236-301)
RMC-6236 vs Docetaxel

Mechanism: TKI
Coord: To be determined
PI: Dr. Arter
Accrual: 0/5

UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
Coordinator: Jenny Choe
Dr. Nagasaka
Accrual: 21/25

ADVANCED/METASTATIC

NTRK 1-3

Open to Accrual

Low Accruing

Pending Activation

1L

2L



ADVANCED/METASTATIC

UCI 25-52 (PYNNALE)

Rezatapopt (PC14586)

Mechanism: selective P53
reactivator

Coord: To be determined

PI: Dr. Arter

Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation



ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

ROS1

1L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 10/16

2L

Early Stage

UCI 24-196 (Nuvation)

Taletrectinib vs Placebo post
complete resection

Mechanism: ROS1 inhibitor

Coord: To be determined

Dr. Arter

Accrual: 0/5

■ Open to Accrual

■ Low Accruing

■ Pending Activation



Advanced / Metastatic

1L

UCI 24-83: CB-NK +
Atezolizumab

Mechanism: PD-L1
Coord: Keagan Buttigieg
PI: Dr. Villalona
Accrual: 0/9

UCI 24-160 Chemo +
Cemiplimab + Agent (a, b, or
none)

Mechanism: PD-L1
Coord: Mindy Chen
PI: Dr. Nagasaka
Accrual: 0/5

UCI 24-195 (Seagen/Pfizer):
PF-08046054/SGN-PDL1V

Mechanism: PD-L1
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 0/6

2L

UCI 23-148: CJRB-01 (oral) +
Pembrolizumab

Mechanism: Live
biotherapeutic product +
Pembrolizumab
Coord: Mindy Chen
PI: Dr. Nagasaka
Accrual: 3/6



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-197 (TNG456
Monotherapy & Combo w/
Abemaciclib)

Mechanism:
Coord: TBD
PI: Dr. Park
Accrual: 0/5

UCI 24-78 (AMG 193 Alone or
Comb w/OtherTherapies)

Mechanism:
Coord: Cassie Smith
PI: Dr. Villalona
Accrual: 1/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-138 (UCLA):
Tarlatamab

Mechanism: BiTE molecule
Coord: TBD
PI: Dr. Park
Accrual: 0/5



 Open to Accrual

 Low Accruing

 Pending Activation

Adjuvant

UCI 23-169 (Merck V940)

Mechanism: Combo of Pembro with V940 drug to treat Stage II, IIIA, IIIB NCSLC

Coordinator: Cassie Smith
PI: Dr. Keshava
Accrual: 0/10

ADVANCED/METASTATIC

UCI 25-89 (IBI3009)

Mechanism: Recombinant Anti-DLL3 Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection

Coordinator: TBD
PI: Dr. Arter
Accrual: 0/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stephanie Fernandez
PI: Dr. Nagasaka
Accrual: 7/82

UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA
Coord: Stephanie Fernandez/
Mindy Chen
Accrual: 12/1753



 Open to Accrual

 Low Accruing

 Pending Activation

Advanced / Metastatic

2L

UCI 24-08 (SPEDOX-6): Dr.
Chow IIT

Mechanism: SPE
Coord: Erin Palmer-Torrison
PI: Dr. Chow
Accrual: 3/67

UCI 25-75 (CRN09682-191) :
Crinetics Pharmaceuticals

Mechanism: NDC
Coord: Michelle Andrade
PI: Dr. Dayyani
Accrual: 0/15